TCGA-CR-6477-01A-11R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- TGF_BETA_SIGNALING+0.420
- COAGULATION+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- KRAS_SIGNALING_UP+0.360
- MYOGENESIS+0.350
- UV_RESPONSE_DN+0.350
- APICAL_JUNCTION+0.330
- COMPLEMENT+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.550
- UNFOLDED_PROTEIN_RESPONSE-0.350
- OXIDATIVE_PHOSPHORYLATION-0.290
- MYC_TARGETS_V1-0.270
- E2F_TARGETS-0.240
- DNA_REPAIR-0.170
- PROTEIN_SECRETION-0.030
- FATTY_ACID_METABOLISM-0.020
- G2M_CHECKPOINT-0.020
- UV_RESPONSE_UP-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0BR-01A-21R-A115-07 | — | C | 0.874 |
| 2 | TCGA-CN-4742-01A-02R-1514-07 | — | — | 0.874 |
| 3 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.868 |
| 4 | SRR23303755 | — | — | 0.865 |
| 5 | SRR1313102 | — | A | 0.860 |
| 6 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.857 |
| 7 | SRR8518124 | — | D | 0.856 |
| 8 | SRR1516079 | — | — | 0.855 |
| 9 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.853 |
| 10 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |